<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255346</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0817</org_study_id>
    <secondary_id>NCI-2012-01353</secondary_id>
    <nct_id>NCT00255346</nct_id>
  </id_info>
  <brief_title>Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)</brief_title>
  <official_title>Therapy of Myeloid Metaplasia-Myelofibrosis, Atypical Chronic Myeloid or Myelomonocytic Leukemia, C-Kit Positive Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (AML-MDS), Hypereosinophilic Syndrome, Polycythemia Vera, and Mastocytosis With Dasatinib (BMS-354825)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if dasatinib can help to control
      myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dasatinib is an experimental anti-cancer drug that is designed to block the function of
      BCR-ABL, which is the abnormal protein responsible for causing leukemia in some cells.

      If you are found to be eligible to take part in this study, you will take dasatinib by mouth
      twice a day. If you have mastocytosis, you will take dasatinib by mouth once a day. A
      treatment cycle will be defined as 4 weeks (28 days) + 7 days. You will be instructed to take
      dasatinib in the morning (between about 6:00 a.m.-10:00 a.m.) and in the evening (between
      about 6:00 p.m.-10:00 p.m.).

      Blood tests (about 2 - 3 teaspoons) will be done once a week for a month, then once a month
      for 5 years, then once every 6 months (if your doctor thinks it is needed) for the remainder
      of your treatment on this study. A bone marrow biopsy will be done after 1-2 months of
      therapy to document response.

      Dasatinib will be given for as long as you are responding. You will be taken off study if the
      disease gets worse or intolerable side effects occur.

      This is an investigational study. Dasatinib is authorized for use in research only. A total
      of 145 patients will take part in this study. All will be treated at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2005</start_date>
  <completion_date type="Actual">March 3, 2017</completion_date>
  <primary_completion_date type="Actual">March 3, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant Response Rate</measure>
    <time_frame>Baseline to completion of 4 week cycle or until disease progression</time_frame>
    <description>Response Rate is complete response plus partial response (CR+PR) for each disease category. Response Evaluation Criteria are as follows:
Systemic Mastocytosis (SM): CR is the improvement of C-Findings, Tryptase &lt;20, and no organomegaly. PR is the improvement of C-Findings.
Acute Myeloid Leukemia (AML)/MDS and CMML: CR is bone marrow blasts &lt;/= 5%, absolute neutrophil count (ANC) &gt;/= 1000 and platelets &gt;/= 100. PR is bone marrow blasts 6-25% but decreased by &gt; 50% and absolute neutrophil count, absolute neutrophil count (ANC) &gt;/= 1000 and platelets &gt;/= 100.
Primary Myelofibrosis (PMF): CR is bone marrow blasts &lt;/= 5%, absolute neutrophil count (ANC) &gt;/= 1000 and platelets &gt;/= 100. CR is PR plus one or more of the following: ANC &gt;/= 1000, decreased platelets by 50%, hemoglobin increase of 2g/dl or reduction splenomegaly and/or hepatomegaly by 50%.
HES/CEL: CR is disappearance of eosinophilia &lt;/= 10%, PR is reduction of eosinophilia by &gt;/= 50%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (Survival)</measure>
    <time_frame>Baseline, once a week for a month, thereafter monthly, up to 10 years</time_frame>
    <description>Response date to loss of response or last follow up.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Agnogenic Myeloid Metaplasia</condition>
  <condition>Myelofibrosis</condition>
  <condition>Hypereosinophilic Syndrome</condition>
  <condition>Polycythemia Vera</condition>
  <condition>Mastocytosis</condition>
  <condition>Leukemia, Myelomonocytic, Chronic</condition>
  <arm_group>
    <arm_group_label>Acute myeloid leukemia (AML)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib 70 mg orally twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDS/CMML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib 70 mg orally twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HES/CEL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib 70 mg orally twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary myelofibrosis (PMF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib 70 mg orally twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systemic Mastocytosis (SM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib 70 mg orally twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib (BMS-354825)</intervention_name>
    <description>70 mg orally twice daily</description>
    <arm_group_label>Acute myeloid leukemia (AML)</arm_group_label>
    <arm_group_label>HES/CEL</arm_group_label>
    <arm_group_label>MDS/CMML</arm_group_label>
    <arm_group_label>Primary myelofibrosis (PMF)</arm_group_label>
    <arm_group_label>Systemic Mastocytosis (SM)</arm_group_label>
    <other_name>Sprycel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients &gt;/= 18 years old who meet the following eligibility criteria

          2. Patients must have one of the following hematopoietic malignancies: C-kit positive
             (10% or more BM or PB MNC positive by flow) acute myeloid leukemia (AML excluding
             acute promyelocytic leukemia) or myelodysplastic syndrome (MDS) of the following
             types: Refractory-relapse AML-MDS including those who fail to achieve Complete
             Response (CR) after the first cycle of induction; Second or subsequent AML-MDS
             refractory-relapse; Newly diagnosed AML-MDS patients over 60 years of age with
             karyotype other than t(15:17), inv16, t(8:21), who do not want chemotherapy.

          3. (Con't from # 2) Patients with MDS who do not want chemotherapy as initial treatment,
             or who are not eligible for the treatments of higher priority.

          4. Agnogenic myeloid metaplasia - myelofibrosis (MMM)

          5. Hypereosinophilic syndrome (HES)

          6. Polycythemia vera (PV)

          7. Mastocytosis

          8. Serum bilirubin less than 2mg%, serum creatinine less than 2mg% unless abnormality is
             considered due to hematologic malignancy by investigator.

          9. Eastern Cooperative Oncology Group (ECOG) Performance Status &lt; 3

         10. Patients must sign an informed consent indicating they are aware of the
             investigational nature of this study, in keeping with the policies of the hospital.

         11. Women of pregnancy potential must practice an effective method of birth control during
             the course of the study, in a manner such that risk of failure is minimized. Prior to
             study enrollment, women of childbearing potential (WOCBP) (defined as not
             post-menopausal for 12 months or no previous surgical sterilization) must be advised
             of the importance of avoiding pregnancy during trial participation and the potential
             risk factors for an unintentional pregnancy.

         12. Continued from #11: In addition, men enrolled on this study should understand the
             risks to any sexual partner of childbearing potential and should practice an effective
             method of birth control.Women and men must continue birth control for the duration of
             the trial and at least 3 months after the last dose of study drug.

         13. Inclusion of women and minorities: As per NIH policy, women and members of minorities
             will be included in this protocol as they are referred in the relevant populations.
             There are no exclusions of women or minorities based on the study objectives.

         14. New York Heart Association (NYHA) Class &lt; 3

         15. Ph negative MPD including chronic myelomonocytic leukemia (CMML).

        Exclusion Criteria:

          1. Pregnant or breast-feeding women are excluded.

          2. All WOCBP MUST have a negative pregnancy test prior to first receiving investigational
             product. If the pregnancy test is positive, the patient must not receive
             investigational product and must not be enrolled in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop M Kantarjian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 16, 2005</study_first_submitted>
  <study_first_submitted_qc>November 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2005</study_first_posted>
  <results_first_submitted>April 17, 2018</results_first_submitted>
  <results_first_submitted_qc>May 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 6, 2019</results_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>targeted therapy</keyword>
  <keyword>leukemia</keyword>
  <keyword>Acute myeloid leukemia (AML)</keyword>
  <keyword>Myelodysplastic syndrome (MDS)</keyword>
  <keyword>Agnogenic myeloid metaplasia - myelofibrosis (MMM)</keyword>
  <keyword>Hypereosinophilic syndrome (HES)</keyword>
  <keyword>Polycythemia vera (PV)</keyword>
  <keyword>Mastocytosis</keyword>
  <keyword>CMML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Mastocytosis</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metaplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 18, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT00255346/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sixty-Seven participants were registered and received the study medication for this study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Acute Myeloid Leukemia (AML)</title>
          <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
        </group>
        <group group_id="P2">
          <title>MDS/CMML</title>
          <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
        </group>
        <group group_id="P3">
          <title>HES/CEL</title>
          <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
        </group>
        <group group_id="P4">
          <title>Primary Myelofibrosis (PMF)</title>
          <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
        </group>
        <group group_id="P5">
          <title>Systemic Mastocytosis (SM)</title>
          <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acute Myeloid Leukemia (AML)</title>
          <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
        </group>
        <group group_id="B2">
          <title>MDS/CMML</title>
          <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
        </group>
        <group group_id="B3">
          <title>HES/CEL</title>
          <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
        </group>
        <group group_id="B4">
          <title>Primary Myelofibrosis (PMF)</title>
          <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
        </group>
        <group group_id="B5">
          <title>Systemic Mastocytosis (SM)</title>
          <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="33"/>
            <count group_id="B6" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" lower_limit="57" upper_limit="91"/>
                    <measurement group_id="B2" value="68" lower_limit="61" upper_limit="75"/>
                    <measurement group_id="B3" value="62" lower_limit="23" upper_limit="75"/>
                    <measurement group_id="B4" value="63" lower_limit="43" upper_limit="77"/>
                    <measurement group_id="B5" value="57" lower_limit="29" upper_limit="74"/>
                    <measurement group_id="B6" value="62" lower_limit="23" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participant Response Rate</title>
        <description>Response Rate is complete response plus partial response (CR+PR) for each disease category. Response Evaluation Criteria are as follows:
Systemic Mastocytosis (SM): CR is the improvement of C-Findings, Tryptase &lt;20, and no organomegaly. PR is the improvement of C-Findings.
Acute Myeloid Leukemia (AML)/MDS and CMML: CR is bone marrow blasts &lt;/= 5%, absolute neutrophil count (ANC) &gt;/= 1000 and platelets &gt;/= 100. PR is bone marrow blasts 6-25% but decreased by &gt; 50% and absolute neutrophil count, absolute neutrophil count (ANC) &gt;/= 1000 and platelets &gt;/= 100.
Primary Myelofibrosis (PMF): CR is bone marrow blasts &lt;/= 5%, absolute neutrophil count (ANC) &gt;/= 1000 and platelets &gt;/= 100. CR is PR plus one or more of the following: ANC &gt;/= 1000, decreased platelets by 50%, hemoglobin increase of 2g/dl or reduction splenomegaly and/or hepatomegaly by 50%.
HES/CEL: CR is disappearance of eosinophilia &lt;/= 10%, PR is reduction of eosinophilia by &gt;/= 50%</description>
        <time_frame>Baseline to completion of 4 week cycle or until disease progression</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute Myeloid Leukemia (AML)</title>
            <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>MDS/CMML</title>
            <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
          </group>
          <group group_id="O3">
            <title>HES/CEL</title>
            <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
          </group>
          <group group_id="O4">
            <title>Primary Myelofibrosis (PMF)</title>
            <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
          </group>
          <group group_id="O5">
            <title>Systemic Mastocytosis (SM)</title>
            <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Response Rate</title>
          <description>Response Rate is complete response plus partial response (CR+PR) for each disease category. Response Evaluation Criteria are as follows:
Systemic Mastocytosis (SM): CR is the improvement of C-Findings, Tryptase &lt;20, and no organomegaly. PR is the improvement of C-Findings.
Acute Myeloid Leukemia (AML)/MDS and CMML: CR is bone marrow blasts &lt;/= 5%, absolute neutrophil count (ANC) &gt;/= 1000 and platelets &gt;/= 100. PR is bone marrow blasts 6-25% but decreased by &gt; 50% and absolute neutrophil count, absolute neutrophil count (ANC) &gt;/= 1000 and platelets &gt;/= 100.
Primary Myelofibrosis (PMF): CR is bone marrow blasts &lt;/= 5%, absolute neutrophil count (ANC) &gt;/= 1000 and platelets &gt;/= 100. CR is PR plus one or more of the following: ANC &gt;/= 1000, decreased platelets by 50%, hemoglobin increase of 2g/dl or reduction splenomegaly and/or hepatomegaly by 50%.
HES/CEL: CR is disappearance of eosinophilia &lt;/= 10%, PR is reduction of eosinophilia by &gt;/= 50%</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (Survival)</title>
        <description>Response date to loss of response or last follow up.</description>
        <time_frame>Baseline, once a week for a month, thereafter monthly, up to 10 years</time_frame>
        <population>The number of participants analyzed for duration of response reflects the number of participants with a response for each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Myeloid Leukemia (AML)</title>
            <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>MDS/CMML</title>
            <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
          </group>
          <group group_id="O3">
            <title>HES/CEL</title>
            <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
          </group>
          <group group_id="O4">
            <title>Primary Myelofibrosis (PMF)</title>
            <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
          </group>
          <group group_id="O5">
            <title>Systemic Mastocytosis (SM)</title>
            <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (Survival)</title>
          <description>Response date to loss of response or last follow up.</description>
          <population>The number of participants analyzed for duration of response reflects the number of participants with a response for each arm.</population>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The duration of response cannot be reported for a single participant for privacy reasons</measurement>
                    <measurement group_id="O3" value="NA">The duration of response cannot be reported for a single participant for privacy reasons</measurement>
                    <measurement group_id="O5" value="13" lower_limit="8" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, up to 10 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dasatinib All Patient Groups</title>
          <description>Dasatinib 70 mg orally twice daily.
Dasatinib (BMS-354825): 70 mg orally twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage CNS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Platelets/Hemoglobin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The outcome measures were collected and reported by participant diagnosis group. The Other Adverse Events and Serious Adverse Events were collected and recorded as a group for all participants registered on the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Hagop Kantarjian, MD/Department Chair</name_or_title>
      <organization>The University of Texas MD Anderson Cancer Center</organization>
      <phone>713-792-7026</phone>
      <email>hkantarjian@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

